-+ 0.00%
-+ 0.00%
-+ 0.00%
Leads Biolabs Plans Opamtistomig-ADC Combination Trials in 2027
Share
Listen to the news
Leads Biolabs Plans Opamtistomig-ADC Combination Trials in 2027
  • Leads Biolabs presented clinical results for cancer immunotherapy opamtistomig at the 2026 Jefferies Global Healthcare Conference in London.
  • Studies showed durable survival benefits across several cancers, including longer survival than historical results in previously treated extrapulmonary neuroendocrine carcinoma.
  • Responses occurred across PD-L1 expression levels, supporting potential use in broader patient populations.
  • No dose-limiting toxicities were observed; the overall safety profile resembled that of PD-(L)1 monoclonal antibodies.
  • Several antibody-drug conjugate combination programs are planned for 2027, including partnerships involving external drug candidates.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611200315PRIMZONEFULLFEED9881969) on November 20, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending